non-TNFi biologic, whereas the current guidelines differentiate treatment recommendations based on whether there was primary or secondary nonresponse to the TNFi. For the treatment of patients with recurrent uveitis, the previous guidelines specified conditional use of infliximab or adalimumab, while the update broadened this recommendation to include TNFi monoclonal antibodies generally. Similarly, for patients with coexisting IBD, the update includes a conditional recommendation for TNFi